These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

802 related items for PubMed ID: 26810188

  • 1. Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer.
    Liu J, Chen X, Ward T, Pegram M, Shen K.
    Tumour Biol; 2016 Jul; 37(7):9825-35. PubMed ID: 26810188
    [Abstract] [Full Text] [Related]

  • 2. Niclosamide inhibits epithelial-mesenchymal transition and tumor growth in lapatinib-resistant human epidermal growth factor receptor 2-positive breast cancer.
    Liu J, Chen X, Ward T, Mao Y, Bockhorn J, Liu X, Wang G, Pegram M, Shen K.
    Int J Biochem Cell Biol; 2016 Feb; 71():12-23. PubMed ID: 26643609
    [Abstract] [Full Text] [Related]

  • 3. Resveratrol Enhances Inhibition Effects of Cisplatin on Cell Migration and Invasion and Tumor Growth in Breast Cancer MDA-MB-231 Cell Models In Vivo and In Vitro.
    Yang MD, Sun Y, Zhou WJ, Xie XZ, Zhou QM, Lu YY, Su SB.
    Molecules; 2021 Apr 12; 26(8):. PubMed ID: 33921192
    [Abstract] [Full Text] [Related]

  • 4. Antrodia camphorata inhibits epithelial-to-mesenchymal transition by targeting multiple pathways in triple-negative breast cancers.
    Hseu YC, Chang GR, Pan JY, Rajendran P, Mathew DC, Li ML, Liao JW, Chen WT, Yang HL.
    J Cell Physiol; 2019 Apr 12; 234(4):4125-4139. PubMed ID: 30146779
    [Abstract] [Full Text] [Related]

  • 5. Luteolin suppresses the metastasis of triple-negative breast cancer by reversing epithelial-to-mesenchymal transition via downregulation of β-catenin expression.
    Lin D, Kuang G, Wan J, Zhang X, Li H, Gong X, Li H.
    Oncol Rep; 2017 Feb 12; 37(2):895-902. PubMed ID: 27959422
    [Abstract] [Full Text] [Related]

  • 6. Tocilizumab potentiates cisplatin cytotoxicity and targets cancer stem cells in triple-negative breast cancer.
    Alraouji NN, Al-Mohanna FH, Ghebeh H, Arafah M, Almeer R, Al-Tweigeri T, Aboussekhra A.
    Mol Carcinog; 2020 Sep 12; 59(9):1041-1051. PubMed ID: 32537818
    [Abstract] [Full Text] [Related]

  • 7. Anti-EMT properties of CoQ0 attributed to PI3K/AKT/NFKB/MMP-9 signaling pathway through ROS-mediated apoptosis.
    Yang HL, Thiyagarajan V, Shen PC, Mathew DC, Lin KY, Liao JW, Hseu YC.
    J Exp Clin Cancer Res; 2019 May 08; 38(1):186. PubMed ID: 31068208
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Inhibition of ERRα suppresses epithelial mesenchymal transition of triple negative breast cancer cells by directly targeting fibronectin.
    Wu YM, Chen ZJ, Liu H, Wei WD, Lu LL, Yang XL, Liang WT, Liu T, Liu HL, Du J, Wang HS.
    Oncotarget; 2015 Sep 22; 6(28):25588-601. PubMed ID: 26160845
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Ketoplatin in triple-negative breast cancer cells MDA-MB-231: High efficacy and low toxicity, and positive impact on inflammatory microenvironment.
    Ma ZY, Song XQ, Hu JJ, Wang DB, Ding XJ, Liu RP, Dai ML, Meng FY, Xu JY.
    Biochem Pharmacol; 2021 Jun 22; 188():114523. PubMed ID: 33741331
    [Abstract] [Full Text] [Related]

  • 16. Cardamonin, a chalcone, inhibits human triple negative breast cancer cell invasiveness by downregulation of Wnt/β-catenin signaling cascades and reversal of epithelial-mesenchymal transition.
    Shrivastava S, Jeengar MK, Thummuri D, Koval A, Katanaev VL, Marepally S, Naidu VGM.
    Biofactors; 2017 Mar 22; 43(2):152-169. PubMed ID: 27580587
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.
    Granados-Principal S, Liu Y, Guevara ML, Blanco E, Choi DS, Qian W, Patel T, Rodriguez AA, Cusimano J, Weiss HL, Zhao H, Landis MD, Dave B, Gross SS, Chang JC.
    Breast Cancer Res; 2015 Feb 22; 17(1):25. PubMed ID: 25849745
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.